Adiponectin attenuates angiotensin II-induced vascular smooth muscle cell remodeling through nitric oxide and the RhoA/ROCK pathway

Frontiers in Pharmacology

Volumn 7, Issue APR, 2016, Pages

  Nour Eldine, Wared ^a,b   Ghantous, Crystal M ^a   Zibara, Kazem ^b   Dib, Leila ^a   Issaa, Hawraa ^a,b   Itani, Hana A ^c   El Zein, Nabil ^b   Zeidan, Asad ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b LEBANESE UNIVERSITY   (Lebanon)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adiponectin; Angiotensin II; Nitric oxide; Remodeling; VSMC

Indexed keywords

ADIPONECTIN; ANGIOTENSIN II; COFILIN; CYCLIC GMP; F ACTIN; G ACTIN; MESSENGER RNA; N ACETYL S NITROSOPENICILLAMINE; NITRIC OXIDE; PROTEIN KINASE ROCK; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE P22PHOX; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE P47PHOX; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG;

ACTIN FILAMENT; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL WALL; CONTROLLED STUDY; ENZYME ACTIVATION; GENE EXPRESSION; HEART PROTECTION; HYPERTROPHY; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; PROTEIN TRANSPORT; RAT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CONTRACTILITY; UPREGULATION; VASCULAR HYPERTROPHY; VASCULAR REMODELING; VASCULAR SMOOTH MUSCLE CELL;

EID: 84967104303     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2016.00086     Document Type: Article

References (74)

1. Bagi, Z., Feher, A., Cassuto, J., Akula, K., Labinskyy, N., Kaley, G., et al. (2011). Increased availability of angiotensin AT 1 receptors leads to sustained arterial constriction to angiotensin II in diabetes - role for Rho-kinase activation. Br. J. Pharmacol. 163, 1059-1068. doi: 10.1111/j.1476-5381.2011.01307.x
2. Carbone, M. L., Bregeon, J., Devos, N., Chadeuf, G., Blanchard, A., Azizi, M., et al. (2015). Angiotensin II activates the RhoA exchange factor Arhgef1 in humans. Hypertension 65, 1273-1278. doi: 10.1161/HYPERTENSIONAHA.114.05065
3. Caselli, C., D'amico, A., Cabiati, M., Prescimone, T., Del Ry, S., and Giannessi, D. (2014). Back to the heart: the protective role of adiponectin. Pharmacol. Res. 82, 9-20. doi: 10.1016/j.phrs.2014.03.003
4. Coles, B., Fielding, C. A., Rose-John, S., Scheller, J., Jones, S. A., and O'donnell, V. B. (2007). Classic interleukin-6 receptor signaling and interleukin-6 trans-signaling differentially control angiotensin II-dependent hypertension, cardiac signal transducer and activator of transcription-3 activation, and vascular hypertrophy in vivo. Am. J. Pathol. 171, 315-325. doi: 10.2353/ajpath.2007.061078
5. Dai, D. F., Johnson, S. C., Villarin, J. J., Chin, M. T., Nieves-Cintron, M., Chen, T., et al. (2011). Mitochondrial oxidative stress mediates angiotensin II-induced cardiac hypertrophy and Galphaq overexpression-induced heart failure. Circ. Res. 108, 837-846. doi: 10.1161/CIRCRESAHA.110.232306
6. Day, B. J., Patel, M., Calavetta, L., Chang, L. Y., and Stamler, J. S. (1999). A mechanism of paraquat toxicity involving nitric oxide synthase. Proc. Natl. Acad. Sci. U.S.A. 96, 12760-12765. doi: 10.1073/pnas.96.22.12760
7. Fujimoto, A., Akifusa, S., Kamio, N., Hirofuji, T., Nonaka, K., and Yamashita, Y. (2010). Involvement of mTOR in globular adiponectin-induced generation of reactive oxygen species. Free Radic. Res. 44, 128-134. doi: 10.3109/10715760903348328
8. Fujita, K., Maeda, N., Sonoda, M., Ohashi, K., Hibuse, T., Nishizawa, H., et al. (2008). Adiponectin protects against angiotensin II-induced cardiac fibrosis through activation of PPAR-alpha. Arterioscler. Thromb. Vasc. Biol. 28, 863-870. doi: 10.1161/ATVBAHA.107.156687
9. Furchgott, R. F. (1983). Role of endothelium in responses of vascular smooth muscle. Circ. Res. 53, 557-573. doi: 10.1161/01.RES.53.5.557
10. Garcha, R. S., Sever, P. S., and Hughes, A. D. (2001). Mechanism of action of angiotensin II in human isolated subcutaneous resistance arteries. Br. J. Pharmacol. 134, 188-196. doi: 10.1038/sj.bjp.0704222
11. Garcia, J. A., and Incerpi, E. K. (2008). Factors and mechanisms involved in left ventricular hypertrophy and the anti-hypertrophic role of nitric oxide. Arq. Bras. Cardiol. 90, 409-416
12. Ghantous, C. M., Azrak, Z., Hanache, S., Abou-Kheir, W., and Zeidan, A. (2015a). Differential role of leptin and adiponectin in cardiovascular system. Int. J. Endocrinol. 2015, 534320. doi: 10.1155/2015/534320
13. Ghantous, C. M., Kobeissy, F. H., Soudani, N., Rahman, F. A., Al-Hariri, M., Itani, H. A., et al. (2015b). Mechanical stretch-induced vascular hypertrophy occurs through modulation of leptin synthesis-mediated ROS formation and GATA-4 nuclear translocation. Front. Pharmacol. 6:240. doi: 10.3389/fphar.2015.00240
14. Heeneman, S., Sluimer, J. C., and Daemen, M. J. (2007). Angiotensin-converting enzyme and vascular remodeling. Circ. Res. 101, 441-454. doi: 10.1161/CIRCRESAHA.107.148338
15. Hingtgen, S. D., Tian, X., Yang, J., Dunlay, S. M., Peek, A. S., Wu, Y., et al. (2006). Nox2-containing NADPH oxidase and Akt activation play a key role in angiotensin II-induced cardiomyocyte hypertrophy. Physiol. Genomics 26, 180-191. doi: 10.1152/physiolgenomics.00029.2005
16. Hofbauer, K. H., Schoof, E., Kurtz, A., and Sandner, P. (2002). Inflammatory cytokines stimulate adrenomedullin expression through nitric oxide-dependent and -independent pathways. Hypertension 39, 161-167. doi: 10.1161/hy1201.097201
17. Homma, N., Nagaoka, T., Morio, Y., Ota, H., Gebb, S. A., Karoor, V., et al. (2007). Endothelin-1 and serotonin are involved in activation of RhoA/Rho kinase signaling in the chronically hypoxic hypertensive rat pulmonary circulation. J. Cardiovasc. Pharmacol. 50, 697-702. doi: 10.1097/FJC.0b013e3181593774
18. Hunter, J. C., Zeidan, A., Javadov, S., Kilic, A., Rajapurohitam, V., and Karmazyn, M. (2009). Nitric oxide inhibits endothelin-1-induced neonatal cardiomyocyte hypertrophy via a RhoA-ROCK-dependent pathway. J. Mol. Cell. Cardiol. 47, 810-818. doi: 10.1016/j.yjmcc.2009.09.012
19. Jin, L., Ying, Z., Hilgers, R. H., Yin, J., Zhao, X., Imig, J. D., et al. (2006). Increased RhoA/Rho-kinase signaling mediates spontaneous tone in aorta from angiotensin II-induced hypertensive rats. J. Pharmacol. Exp. Ther. 318, 288-295. doi: 10.1124/jpet.105.100735
20. Jones, S. P., and Bolli, R. (2006). The ubiquitous role of nitric oxide in cardioprotection. J. Mol. Cell. Cardiol. 40, 16-23. doi: 10.1016/j.yjmcc.2005.09.011
21. Kapakos, G., Bouallegue, A., Daou, G. B., and Srivastava, A. K. (2010). Modulatory role of nitric oxide/cGMP system in endothelin-1-induced signaling responses in vascular smooth muscle cells. Curr. Cardiol. Rev. 6, 247-254. doi: 10.2174/157340310793566055
22. Kawai, T., Ohishi, M., Takeya, Y., Onishi, M., Ito, N., Yamamoto, K., et al. (2013). Adiponectin single nucleotide polymorphism is a genetic risk factor for stroke through high pulse wave pressure: a cohort study. J. Atheroscler. Thromb. 20, 152-160. doi: 10.5551/jat.14696
23. Kim, D. H., Kim, C., Ding, E. L., Townsend, M. K., and Lipsitz, L. A. (2013). Adiponectin levels and the risk of hypertension: a systematic review and meta-analysis. Hypertension 62, 27-32. doi: 10.1161/HYPERTENSIONAHA.113.01453
24. Kitaoka, H., Kubo, T., Okawa, M., Yamasaki, N., Matsumura, Y., Nishinaga, M., et al. (2010). Plasma adiponectin levels and left ventricular remodeling in hypertrophic cardiomyopathy. Int. Heart J. 51, 51-55. doi: 10.1536/ihj.51.51
25. Kuwahara, K., Saito, Y., Nakagawa, O., Kishimoto, I., Harada, M., Ogawa, E., et al. (1999). The effects of the selective ROCK inhibitor, Y27632, on ET-1-induced hypertrophic response in neonatal rat cardiac myocytes-possible involvement of Rho/ROCK pathway in cardiac muscle cell hypertrophy. FEBS Lett. 452, 314-318. doi: 10.1016/S0014-5793(99)00680-8
26. Lambeth, J. D. (2004). NOX enzymes and the biology of reactive oxygen. Nat. Rev. Immunol. 4, 181-189. doi: 10.1038/nri1312
27. Lavigne, M. C., Malech, H. L., Holland, S. M., and Leto, T. L. (2001). Genetic demonstration of p47phox-dependent superoxide anion production in murine vascular smooth muscle cells. Circulation 104, 79-84. doi: 10.1161/01.CIR.104.1.79
28. Li, L., Gao, P., Zhang, H., Chen, H., Zheng, W., Lv, X., et al. (2011). SIRT1 inhibits angiotensin II-induced vascular smooth muscle cell hypertrophy. Acta Biochim. Biophys. Sin. (Shanghai) 43, 103-109. doi: 10.1093/abbs/gmq104
29. Li, L., Zhang, Z. G., Lei, H., Wang, C., Wu, L. P., Wang, J. Y., et al. (2013). Angiotensin II reduces cardiac AdipoR1 expression through AT1 receptor/ROS/ERK1/2/c-Myc pathway. PLoS ONE 8:e49915. doi: 10.1371/journal.pone.0049915
30. Lin, L. Y., Lin, C. Y., Su, T. C., and Liau, C. S. (2004). Angiotensin II-induced apoptosis in human endothelial cells is inhibited by adiponectin through restoration of the association between endothelial nitric oxide synthase and heat shock protein 90. FEBS Lett. 574, 106-110. doi: 10.1016/j.febslet.2004.08.012
31. Maruhashi, T., Noma, K., Iwamoto, Y., Iwamoto, A., Oda, N., Kajikawa, M., et al. (2014). Critical role of exogenous nitric oxide in ROCK activity in vascular smooth muscle cells. PLoS ONE 9:e109017. doi: 10.1371/journal.pone.0109017
32. Matsuno, K., Yamada, H., Iwata, K., Jin, D., Katsuyama, M., Matsuki, M., et al. (2005). Nox1 is involved in angiotensin II-mediated hypertension: a study in Nox1-deficient mice. Circulation 112, 2677-2685. doi: 10.1161/CIRCULATIONAHA.105.573709
33. Mayer, B., Pfeiffer, S., Schrammel, A., Koesling, D., Schmidt, K., and Brunner, F. (1998). A new pathway of nitric oxide/cyclic GMP signaling involving S-nitrosoglutathione. J. Biol. Chem. 273, 3264-3270. doi: 10.1074/jbc.273.6.3264
34. Menzaghi, C., Trischitta, V., and Doria, A. (2007). Genetic influences of adiponectin on insulin resistance, type 2 diabetes, and cardiovascular disease. Diabetes Metab. Res. Rev. 56, 1198-1209
35. Mizuno, Y., Isotani, E., Huang, J., Ding, H., Stull, J. T., and Kamm, K. E. (2008). Myosin light chain kinase activation and calcium sensitization in smooth muscle in vivo. Am. J. Physiol. Cell Physiol. 295, C358-C364. doi: 10.1152/ajpcell.90645.2007
36. Molkentin, J. D., and Dorn, G. W. II (2001). Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu. Rev. Physiol. 63, 391-426. doi: 10.1146/annurev.physiol.63.1.391
37. Momi, S., Monopoli, A., Alberti, P. F., Falcinelli, E., Corazzi, T., Conti, V., et al. (2012). Nitric oxide enhances the anti-inflammatory and anti-atherogenic activity of atorvastatin in a mouse model of accelerated atherosclerosis. Cardiovasc. Res. 94, 428-438. doi: 10.1093/cvr/cvs100
38. Montezano, A. C., and Touyz, R. M. (2012). Molecular mechanisms of hypertension-reactive oxygen species and antioxidants: a basic science update for the clinician. Can. J. Cardiol. 28, 288-295. doi: 10.1016/j.cjca.2012.01.017
39. Murthy, K. S., Zhou, H., Grider, J. R., and Makhlouf, G. M. (2003). Inhibition of sustained smooth muscle contraction by PKA and PKG preferentially mediated by phosphorylation of RhoA. Am. J. Physiol. Gastrointest. Liver Physiol. 284, G1006-G1016. doi: 10.1152/ajpgi.00465.2002
40. Ohashi, K., Kihara, S., Ouchi, N., Kumada, M., Fujita, K., Hiuge, A., et al. (2006). Adiponectin replenishment ameliorates obesity-related hypertension. Hypertension 47, 1108-1116. doi: 10.1161/01.HYP.0000222368.43759.a1
41. Ohashi, K., Ouchi, N., and Matsuzawa, Y. (2011). Adiponectin and hypertension. Am. J. Hypertens. 24, 263-269. doi: 10.1038/ajh.2010.216
42. Ouchi, N., Kihara, S., Arita, Y., Maeda, K., Kuriyama, H., Okamoto, Y., et al. (1999). Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100, 2473-2476. doi: 10.1161/01.CIR.100.25.2473
43. Ouchi, N., Shibata, R., and Walsh, K. (2006). Targeting adiponectin for cardioprotection. Expert Opin. Ther. Targets 10, 573-581. doi: 10.1517/14728222.10.4.573
44. Pedrinelli, R., Ballo, P., Fiorentini, C., Denti, S., Galderisi, M., Ganau, A., et al. (2012). Hypertension and acute myocardial infarction: an overview. J. Cardiovasc. Med. (Hagerstown) 13, 194-202. doi: 10.2459/JCM.0b013e3283511ee2
45. Sakamoto, K., Hori, M., Izumi, M., Oka, T., Kohama, K., Ozaki, H., et al. (2003). Inhibition of high K+-induced contraction by the ROCKs inhibitor Y-27632 in vascular smooth muscle: possible involvement of ROCKs in a signal transduction pathway. J. Pharmacol. Sci. 92, 56-69. doi: 10.1254/jphs.92.56
46. Schiffrin, E. L., and Touyz, R. M. (2003). Inflammation and vascular hypertrophy induced by angiotensin II: role of NADPH oxidase-derived reactive oxygen species independently of blood pressure elevation? Arterioscler. Thromb. Vasc. Biol. 23, 707-709. doi: 10.1161/01.ATV.0000069907.12357.7E
47. Shetty, S., Kusminski, C. M., and Scherer, P. E. (2009). Adiponectin in health and disease: evaluation of adiponectin-targeted drug development strategies. Trends Pharmacol. Sci. 30, 234-239. doi: 10.1016/j.tips.2009.02.004
48. Shibata, R., Ouchi, N., Ito, M., Kihara, S., Shiojima, I., Pimentel, D. R., et al. (2004). Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat. Med. 10, 1384-1389. doi: 10.1038/nm1137
49. Shibata, R., Sato, K., Pimentel, D. R., Takemura, Y., Kihara, S., Ohashi, K., et al. (2005). Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat. Med. 11, 1096-1103. doi: 10.1038/nm1295
50. Tajtakova, M., Petrasova, D., Pidanicova, A., Gallovicova, A., Blanarova, C., and Petrovicova, J. (2010). Serum levels of leptin, adiponectin, retinol binding protein 4 and leptin/adiponectin molar ratio as another possible marker of insulin resistance in obese. Bratisl. Lek. Listy 111, 212-215
51. Tanaka, A., and Node, K. (2015). A novel cardioprotective mechanism of exogenous nitric oxide: inhibition of Rho-associated kinase activity. Hypertens Res. 38, 461-462. doi: 10.1038/hr.2015.61
52. Thomas, M., Gavrila, D., McCormick, M. L., Miller, F. J. Jr., Daugherty, A., Cassis, L. A., et al. (2006). Deletion of p47phox attenuates angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-deficient mice. Circulation 114, 404-413. doi: 10.1161/CIRCULATIONAHA.105.607168
53. Touyz, R. M. (2003). The role of angiotensin II in regulating vascular structural and functional changes in hypertension. Curr. Hypertens. Rep. 5, 155-164. doi: 10.1007/s11906-003-0073-2
54. Touyz, R. M. (2005). Reactive oxygen species as mediators of calcium signaling by angiotensin II: implications in vascular physiology and pathophysiology. Antioxid. Redox Signal. 7, 1302-1314. doi: 10.1089/ars.2005.7.1302
55. Touyz, R. M., and Briones, A. M. (2011). Reactive oxygen species and vascular biology: implications in human hypertension. Hypertens Res. 34, 5-14. doi: 10.1038/hr.2010.201
56. Touyz, R. M., Yao, G., Quinn, M. T., Pagano, P. J., and Schiffrin, E. L. (2005). p47phox associates with the cytoskeleton through cortactin in human vascular smooth muscle cells: role in NAD(P)H oxidase regulation by angiotensin II. Arterioscler. Thromb. Vasc. Biol. 25, 512-518. doi: 10.1161/01.ATV.0000154141.66879.98
57. Tziros, C., and Freedman, J. E. (2006). The many antithrombotic actions of nitric oxide. Curr. Drug Targets 7, 1243-1251. doi: 10.2174/138945006778559111
58. Uchida, T., Shimizu, M., Sakai, Y., Nakano, T., Hara, K., Takebayashi, K., et al. (2008). Effects of losartan on serum total and high-molecular weight adiponectin concentrations in hypertensive patients with metabolic syndrome. Metabolism 57, 1278-1285. doi: 10.1016/j.metabol.2008.04.024
59. Ushio-Fukai, M., Zafari, A. M., Fukui, T., Ishizaka, N., and Griendling, K. K. (1996). p22phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. J. Biol. Chem. 271, 23317-23321. doi: 10.1074/jbc.271.38.23317
60. Van Heerebeek, L., Meischl, C., Stooker, W., Meijer, C. J., Niessen, H. W., and Roos, D. (2002). NADPH oxidase(s): new source(s) of reactive oxygen species in the vascular system? J. Clin. Pathol. 55, 561-568. doi: 10.1136/jcp.55.8.561
61. Van Hove, C. E., Van Der Donckt, C., Herman, A. G., Bult, H., and Fransen, P. (2009). Vasodilator efficacy of nitric oxide depends on mechanisms of intracellular calcium mobilization in mouse aortic smooth muscle cells. Br. J. Pharmacol. 158, 920-930. doi: 10.1111/j.1476-5381.2009.00396.x
62. Wang, C., Li, L., Zhang, Z. G., Fan, D., Zhu, Y., and Wu, L. L. (2010). Globular adiponectin inhibits angiotensin II-induced nuclear factor kappaB activation through AMP-activated protein kinase in cardiac hypertrophy. J. Cell. Physiol. 222, 149-155. doi: 10.1002/jcp.21931
63. Yamakawa, T., Tanaka, S., Numaguchi, K., Yamakawa, Y., Motley, E. D., Ichihara, S., et al. (2000). Involvement of Rho-kinase in angiotensin II-induced hypertrophy of rat vascular smooth muscle cells. Hypertension 35, 313-318. doi: 10.1161/01.HYP.35.1.313
64. Yamauchi, T., and Kadowaki, T. (2013). Adiponectin receptor as a key player in healthy longevity and obesity-related diseases. Cell Metab. 17, 185-196. doi: 10.1016/j.cmet.2013.01.001
65. Yuan, F., Li, Y. N., Liu, Y. H., Yi, B., Tian, J. W., and Liu, F. Y. (2012). Adiponectin inhibits the generation of reactive oxygen species induced by high glucose and promotes endothelial NO synthase formation in human mesangial cells. Mol. Med. Rep. 6, 449-453. doi: 10.3892/mmr.2012.931
66. Zeidan, A., Gan, X. T., Thomas, A., and Karmazyn, M. (2014). Prevention of RhoA activation and cofilin-mediated actin polymerization mediates the antihypertrophic effect of adenosine receptor agonists in angiotensin II- and endothelin-1-treated cardiomyocytes. Mol. Cell. Biochem. 385, 239-248. doi: 10.1007/s11010-013-1832-2
67. Zeidan, A., Javadov, S., Chakrabarti, S., and Karmazyn, M. (2008). Leptin-induced cardiomyocyte hypertrophy involves selective caveolae and RhoA/ROCK-dependent p38 MAPK translocation to nuclei. Cardiovasc. Res. 77, 64-72. doi: 10.1093/cvr/cvm020
68. Zeidan, A., Javadov, S., and Karmazyn, M. (2006). Essential role of Rho/ROCK-dependent processes and actin dynamics in mediating leptin-induced hypertrophy in rat neonatal ventricular myocytes. Cardiovasc. Res. 72, 101-111. doi: 10.1016/j.cardiores.2006.06.024
69. Zeidan, A., Nordstrom, I., Albinsson, S., Malmqvist, U., Sward, K., and Hellstrand, P. (2003). Stretch-induced contractile differentiation of vascular smooth muscle: sensitivity to actin polymerization inhibitors. Am. J. Physiol. Cell Physiol. 284, C1387-C1396. doi: 10.1152/ajpcell.00508.2002
70. Zeidan, A., Paylor, B., Steinhoff, K. J., Javadov, S., Rajapurohitam, V., Chakrabarti, S., et al. (2007). Actin cytoskeleton dynamics promotes leptin-induced vascular smooth muscle hypertrophy via RhoA/ROCK- and phosphatidylinositol 3-kinase/protein kinase B-dependent pathways. J. Pharmacol. Exp. Ther. 322, 1110-1116. doi: 10.1124/jpet.107.122440
71. Zeidan, A., Purdham, D. M., Rajapurohitam, V., Javadov, S., Chakrabarti, S., and Karmazyn, M. (2005). Leptin induces vascular smooth muscle cell hypertrophy through angiotensin II- and endothelin-1-dependent mechanisms and mediates stretch-induced hypertrophy. J. Pharmacol. Exp. Ther. 315, 1075-1084. doi: 10.1124/jpet.105.091561
72. 2. Hypertension 46, 732-737. doi: 10.1161/01.HYP.0000182660.74266.6d
73. Zhou, M. S., Schulman, I. H., and Raij, L. (2004). Nitric oxide, angiotensin II, and hypertension. Semin. Nephrol. 24, 366-378. doi: 10.1016/j.semnephrol.2004.04.008
74. Zhu, W., Cheng, K. K., Vanhoutte, P. M., Lam, K. S., and Xu, A. (2008). Vascular effects of adiponectin: molecular mechanisms and potential therapeutic intervention. Clin. Sci. (Lond.) 114, 361-374. doi: 10.1042/CS20070347